Directly from EULAR 2024: 8 out of 10 Patients with RA Achieve Sustained Remission at Month 12 with Upadacitinib
In real-world practice, >79% of patients with moderate to severe rheumatoid arthritis (RA)were able to achieve Disease Activity Score-28 for Rheumatoid Arthritis with C-reactive protein (DAS28-CRP) remission by 6 months, which was maintained through month 12, according to data presented at the 2024 European Congress of Rheumatology (EULAR). These data boast a favorable benefit-risk profile for the drug and is consistent with the findings from the previous phase 3 clinical trials.
“Upadacitinib, an oral reversible Janus kinase [JAK] inhibitor, has shown efficacy with an acceptable safety profile in patients with moderate-to-severe RA in the SELECT clinical trials,” wrote a team of investigators led by Andrew Östör, MD, associate professor in the Department of Medicine at Monash University. “However, data on the effectiveness and safety of upadacitinib in a real-world setting, which may differ from clinical trials, are limited.”
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
